356 related articles for article (PubMed ID: 30593513)
1. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.
Hurvitz SA; O'Shaughnessy J; Mason G; Yardley DA; Jahanzeb M; Brufsky A; Rugo HS; Swain SM; Kaufman PA; Tripathy D; Chu L; Li H; Antao V; Cobleigh M
Clin Cancer Res; 2019 Apr; 25(8):2433-2441. PubMed ID: 30593513
[TBL] [Abstract][Full Text] [Related]
2. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
3. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs.
Cobleigh M; Yardley DA; Brufsky AM; Rugo HS; Swain SM; Kaufman PA; Tripathy D; Hurvitz SA; O'Shaughnessy J; Mason G; Antao V; Li H; Chu L; Jahanzeb M
Clin Cancer Res; 2020 Mar; 26(5):1105-1113. PubMed ID: 31772121
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
Brufsky AM; Mayer M; Rugo HS; Kaufman PA; Tan-Chiu E; Tripathy D; Tudor IC; Wang LI; Brammer MG; Shing M; Yood MU; Yardley DA
Clin Cancer Res; 2011 Jul; 17(14):4834-43. PubMed ID: 21768129
[TBL] [Abstract][Full Text] [Related]
5. Defining prognosis for women with breast cancer and CNS metastases by HER2 status.
Dawood S; Broglio K; Esteva FJ; Ibrahim NK; Kau SW; Islam R; Aldape KD; Yu TK; Hortobagyi GN; Gonzalez-Angulo AM
Ann Oncol; 2008 Jul; 19(7):1242-1248. PubMed ID: 18334512
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and outcome of HER2+ breast cancer with CNS metastases.
Masci G; Agostinetto E; Giordano L; Bottai G; Torrisi R; Losurdo A; De Sanctis R; Navarria P; Scorsetti M; Zuradelli M; de Rose F; Bello L; Santoro A
Future Oncol; 2020 Mar; 16(7):269-279. PubMed ID: 32043375
[No Abstract] [Full Text] [Related]
7. The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Tripathy D; Rugo HS; Kaufman PA; Swain S; O'Shaughnessy J; Jahanzeb M; Mason G; Beattie M; Yoo B; Lai C; Masaquel A; Hurvitz S
BMC Cancer; 2014 May; 14():307. PubMed ID: 24885258
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.
Olson EM; Najita JS; Sohl J; Arnaout A; Burstein HJ; Winer EP; Lin NU
Breast; 2013 Aug; 22(4):525-31. PubMed ID: 23352568
[TBL] [Abstract][Full Text] [Related]
9. Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.
Kaufman PA; Hurvitz SA; O'Shaughnessy J; Mason G; Yardley DA; Brufsky AM; Rugo HS; Cobleigh M; Swain SM; Tripathy D; Morris A; Antao V; Li H; Jahanzeb M
Breast Cancer Res Treat; 2021 Jul; 188(1):179-190. PubMed ID: 33641083
[TBL] [Abstract][Full Text] [Related]
10. Metastatic breast cancer subtypes and central nervous system metastases.
Aversa C; Rossi V; Geuna E; Martinello R; Milani A; Redana S; Valabrega G; Aglietta M; Montemurro F
Breast; 2014 Oct; 23(5):623-8. PubMed ID: 24993072
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for central nervous system metastasis in patients with metastatic breast cancer.
Sezgin C; Gokmen E; Esassolak M; Ozdemir N; Goker E
Med Oncol; 2007; 24(2):155-61. PubMed ID: 17848738
[TBL] [Abstract][Full Text] [Related]
12. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.
Musolino A; Ciccolallo L; Panebianco M; Fontana E; Zanoni D; Bozzetti C; Michiara M; Silini EM; Ardizzoni A
Cancer; 2011 May; 117(9):1837-46. PubMed ID: 21509760
[TBL] [Abstract][Full Text] [Related]
13. Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort.
Pasquier D; Darlix A; Louvel G; Fraisse J; Jacot W; Brain E; Petit A; Mouret-Reynier MA; Goncalves A; Dalenc F; Deluche E; Fresnel JS; Augereau P; Ferrero JM; Geffrelot J; Fumet JD; Lecouillard I; Cottu P; Petit T; Uwer L; Jouannaud C; Leheurteur M; Dieras V; Robain M; Mouttet-Audouard R; Bachelot T; Courtinard C
Eur J Cancer; 2020 Jan; 125():22-30. PubMed ID: 31835235
[TBL] [Abstract][Full Text] [Related]
14. Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.
Serpico D; Porcu L; Tessari A; Gevorgyan A; Bregni G; Galli G; de Braud F; Torri V; Di Cosimo S
Clin Transl Oncol; 2015 Jul; 17(7):530-8. PubMed ID: 25604128
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
18. Overall Survival Benefit from Trastuzumab-Based Treatment in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis.
Lv S; Wang Y; Sun T; Wan D; Sheng L; Li W; Zhu H; Li Y; Lu J
Oncol Res Treat; 2018; 41(7-8):450-455. PubMed ID: 29902791
[TBL] [Abstract][Full Text] [Related]
19. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.
Darlix A; Louvel G; Fraisse J; Jacot W; Brain E; Debled M; Mouret-Reynier MA; Goncalves A; Dalenc F; Delaloge S; Campone M; Augereau P; Ferrero JM; Levy C; Fumet JD; Lecouillard I; Cottu P; Petit T; Uwer L; Jouannaud C; Leheurteur M; Dieras V; Robain M; Chevrot M; Pasquier D; Bachelot T
Br J Cancer; 2019 Dec; 121(12):991-1000. PubMed ID: 31719684
[TBL] [Abstract][Full Text] [Related]
20. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
